Formulation and Evaluation of Mucoadhesive Matrix Tablets Containing Piribedil

Mucoadhesive drug delivery systems have been thoroughly investigated for their capacity to extend the residence time of the dosage form at the absorption site, thereby improving bioavailability and patient compliance. This study aimed to develop and evaluate mucoadhesive tablets containing the anti-Parkinson's drug piribedil, using different mucoadhesive polymers. The matrix tablets were prepared by the direct compression method and evaluated for various physicochemical properties, in vitro drug release, and ex vivo mucoadhesive strength. Pre-compression evaluations, including bulk density, tapped density, angle of repose, compressibility index, and Hausner's ratio, demonstrated good flow properties of the powder blends. Post-compression analyses confirmed uniformity in tablet hardness, weight variation, thickness, drug content, and friability, all within acceptable limits. The in vitro drug release profile varied with polymer type and concentration. Tablets with xanthan gum exhibited >90% drug release within 6 hours, while those with HPMC K4M and chitosan showed sustained release profiles. Mucoadhesive strength and swelling indices indicated optimal performance, with the formulation containing HPMC K4M exhibiting superior bioadhesion and controlled drug release. The stability studies conducted on the optimized formulation (F6) revealed consistent drug content and no significant degradation over three months, adhering to ICH guidelines. These findings highlight the potential of buccal tablets for effective and patient-friendly drug delivery.